ReviewJournal of hospital medicine2016
Fecal microbiota transplantation for the treatment of Clostridium difficile infection.
Review in Journal of hospital medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Trial
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Factors associated with failure of fecal microbiota transplant for recurrentTherapeutic advances in gastroenterology · 2025Article
- Efficacy and safety of faecal microbiota transplantation (FMT) in recurrentPrzeglad gastroenterologiczny · 2025Article
- The current landscape of fecal microbiota transplantation in treating inflammatory bowel disease.Translational gastroenterology and hepatology · 2025Review
- A review of inflammatory bowel diseases in humans and pets: treatment strategies.Veterinary research forum : an international quarterly journal · 2025Review
- Diet Drives Gut Bacterial Diversity of Wild and Semi-Captive Common Cranes (Animals : an open access journal from MDPI · 2024Article
- The impact of faecal diversion on the gut microbiome: a systematic review.Gut microbiome (Cambridge, England) · 2024Review
- Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease.Journal of microbiology and biotechnology · 2023Review
- Clostridioides (Clostridium) difficile: A silent nosocomial pathogen.Saudi medical journal · 2023Review
- Mucosal Vaccination Strategies againstVaccines · 2023Review
- A review of epidemiological models of Clostridioides difficile transmission and control (2009-2021).Anaerobe · 2022Review
- Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis.Frontiers in molecular neuroscience · 2022Review
- Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation.Frontiers in cellular and infection microbiology · 2021Review
- Applications of gut microbiota in patients with hematopoietic stem-cell transplantation.Experimental hematology & oncology · 2020Review
- Microbiota and Obesity: Where Are We Now?Biology · 2020Review
- GABAergic but not Antidepressant Medications Increase Risk forOpen forum infectious diseases · 2020Article
- Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation.Therapeutic advances in hematology · 2020Review
- Decoding the microbiome for the development of translational applications: Overview, challenges and pitfalls.Journal of biosciences · 2019Review
- Recent Advances in Anti-Aging Medicine.Korean journal of family medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Clostridium difficile, a major cause of healthcare-associated diarrhea due to perturbation of the normal gastrointestinal microbiome, is responsible for significant morbidity, mortality, and healthcare expenditures. The incidence and severity of C difficile infection (CDI) is increasing, and recurrent disease is common. Recurrent infection can be difficult to manage with conventional antibiotic therapy. Fecal microbiota transplantation (FMT), which involves instillation of stool from a healthy donor into the gastrointestinal tract of the patient, restores the gut microbiome to a healthy state. FMT has emerged as a promising new treatment for CDI. There are limited data on FMT for treatment of primary CDI, but FMT appears safe and effective for recurrent CDI. The safety and efficacy of FMT in patients with severe primary or severe recurrent CDI has not been established. Patients with inflammatory bowel disease (IBD) who undergo FMT for CDI may be at increased risk of IBD flare, and caution should be exercised with use of FMT in that population. The long-term safety of FMT is unknown; thus, rigorously conducted prospective studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.